United Kingdom · Delayed Price · Currency is GBP · Price in GBX Renalytix Statistics
Total Valuation
Renalytix has a market cap or net worth of GBP 32.31 million. The enterprise value is 35.55 million.
| Market Cap | 32.31M |
| Enterprise Value | 35.55M |
Important Dates
The next estimated earnings date is Thursday, December 24, 2026.
| Earnings Date | Dec 24, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Renalytix has 603.83 million shares outstanding. The number of shares has increased by 49.15% in one year.
| Current Share Class | 603.83M |
| Shares Outstanding | 603.83M |
| Shares Change (YoY) | +49.15% |
| Shares Change (QoQ) | +14.13% |
| Owned by Insiders (%) | 2.23% |
| Owned by Institutions (%) | 49.45% |
| Float | 431.30M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 14.29 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 15.72 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.61
| Current Ratio | 0.61 |
| Quick Ratio | 0.39 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -19.86 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -162.38% |
| Return on Invested Capital (ROIC) | -2,482.14% |
| Return on Capital Employed (ROCE) | 1,737.50% |
| Weighted Average Cost of Capital (WACC) | 12.42% |
| Revenue Per Employee | 49,154 |
| Profits Per Employee | -232,664 |
| Employee Count | 46 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 5.14 |
Taxes
| Income Tax | -376,850 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -26.19% in the last 52 weeks. The beta is 1.55, so Renalytix's price volatility has been higher than the market average.
| Beta (5Y) | 1.55 |
| 52-Week Price Change | -26.19% |
| 50-Day Moving Average | 5.58 |
| 200-Day Moving Average | 3.60 |
| Relative Strength Index (RSI) | 47.76 |
| Average Volume (20 Days) | 897,164 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Renalytix had revenue of GBP 2.26 million and -10.70 million in losses. Loss per share was -0.03.
| Revenue | 2.26M |
| Gross Profit | 904,440 |
| Operating Income | -10.48M |
| Pretax Income | -11.08M |
| Net Income | -10.70M |
| EBITDA | -10.33M |
| EBIT | -10.48M |
| Loss Per Share | -0.03 |
Balance Sheet
The company has 1.06 million in cash and 4.30 million in debt, with a net cash position of -3.24 million or -0.01 per share.
| Cash & Cash Equivalents | 1.06M |
| Total Debt | 4.30M |
| Net Cash | -3.24M |
| Net Cash Per Share | -0.01 |
| Equity (Book Value) | -4.75M |
| Book Value Per Share | -0.01 |
| Working Capital | -1.58M |
Cash Flow
In the last 12 months, operating cash flow was -8.22 million and capital expenditures -75,370, giving a free cash flow of -8.29 million.
| Operating Cash Flow | -8.22M |
| Capital Expenditures | -75,370 |
| Depreciation & Amortization | 149,734 |
| Net Borrowing | -74,867 |
| Free Cash Flow | -8.29M |
| FCF Per Share | -0.01 |
Margins
| Gross Margin | 40.00% |
| Operating Margin | -463.33% |
| Pretax Margin | -490.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Renalytix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -49.15% |
| Shareholder Yield | -49.15% |
| Earnings Yield | -48.84% |
| FCF Yield | -25.66% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Renalytix has an Altman Z-Score of -62.9 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -62.9 |
| Piotroski F-Score | 3 |